Vidhya Pharmachem Private Limited - Due diligence report
A 360° intelligence report on Vidhya Pharmachem Private Limited: trust score, financial health, credit view, compliance, directors, growth a…
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Vidhya Pharmachem Private Limited — 360° Intelligence Report
Generated from MCA filings & public recordsVidhya Pharmachem Private Limited is assessed as Moderate with a Trust Score of 60/100. Vidhya Pharmachem Private Limited is an active private limited indian non-government company incorporated in 1999, operating in the Pharma sector. Processed financial statements are not yet available for trend analysis. Based on MCA filings and public records, it currently shows a high compliance risk and high financial risk profile.
Report generated on 25 Jul 2026 from the latest processed filings. Vidhya Pharmachem Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
Score Card
Higher is safer · rule-based & explainableFinancial Intelligence Dashboard
Standalone · 1 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
Credit & Compliance Intelligence
Why the scores are what they are- Negative operating earnings - debt service depends on external support.
- Open charges exceed net worth - secured lenders rank ahead.
Charges position: 16 open (188.55 cr) · 0 satisfied (-).
| Lender | Charges | Amount |
|---|---|---|
| Union Bank Of India | 5 | 48.0 cr |
| Bank Of Baroda | 5 | 48.0 cr |
| Oriental Bank Of Commerce | 1 | 48.0 cr |
| Axis Bank Limited | 2 | 48.0 cr |
| Sbi Global Factors Limited | 1 | 48.0 cr |
| S. E. Investments Limited | 2 | 48.0 cr |
- Company status is Active as per MCA.
- Marked ACTIVE non-compliant (INC-22A).
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: BANKS, MCA, DRT.
- Litigation present in 3 court forum(s).
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| MAHESH NAVINCHANDRA AVALANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HARKARAN SINGH SHEKHAWAT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 2 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
Ownership & Group Intelligence
As per FY 2023 annual returnPromoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Hrishabh Pharma Private Limited | Holding Company | 74.00% |
Full shareholding pattern, group structure & capital events →
Risk Intelligence Center
Growth N/A · Distress 90Stakeholder Verdicts
Vendor · Banker · Investor- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
- Debt capacity assessed from filed statements.
- 16 open charge(s) of 188.55 cr already registered.
- Compliance gaps should be priced into terms.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management team looks stable.
MCA Filings & Events Timeline
Latest 15 eventsKey Observations
Auto-generated from the data aboveWho Uses This Report
CA · CS · Banker · Investor · VendorVerify Vidhya Pharmachem Private Limited before audits and certifications: compliance score 30/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Track statutory health of Vidhya Pharmachem Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Current banker verdict: Enhanced diligence advised. Credit risk score 30/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investor view: Limited indicators at present. Growth score n/a, margin trends, ownership structure and peer set for Vidhya Pharmachem Private Limited - screening before a deeper diligence.
Vendor verdict: Review suggested. Trust score 60/100, distress signals and MSME payment-delay disclosures - know whether Vidhya Pharmachem Private Limited pays its suppliers before you extend credit terms.
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Vidhya Pharmachem Private Limited - groundwork for KYC, onboarding and disputes.
Frequently Asked Questions
Is Vidhya Pharmachem Private Limited an active company?
Vidhya Pharmachem Private Limited has MCA status “Active” with a compliance score of 30/100 (Caution Indicated).
Is Vidhya Pharmachem Private Limited financially healthy?
Vidhya Pharmachem Private Limited has a Financial Health Score of 45/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Vidhya Pharmachem Private Limited?
Its overall Trust Score is 60/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Vidhya Pharmachem Private Limited?
The ultimate holding entity is Hrishabh Pharma Private Limited. 2 active director(s) are on record.
Does Vidhya Pharmachem Private Limited have loans or charges against its assets?
16 open charge(s) are registered against its assets.
Is Vidhya Pharmachem Private Limited up to date with its ROC filings?
Marked ACTIVE non-compliant (INC-22A). Overall compliance score: 30/100 (Caution Indicated).
Is it risky to lend to Vidhya Pharmachem Private Limited?
Its Credit Risk Score is 30/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.